Skip to main content
main-content
Top

18-05-2020 | Oncology | News | Article

News in brief

​​​​​​​ESMO-CoCARE cancer, COVID-19 registry launched

Author:
Shreeya Nanda

medwireNews: The ESMO-CoCARE registry has been initiated to better understand the impact of COVID-19 on people with cancer.

“Ultimately the project aims to propose approaches to mitigate the risks related to COVID-19 in cancer patients,” the organization states on the website.

To fulfill this purpose, the international collaborative project will collate data on cancer patients with a suspected or confirmed diagnosis of SARS-CoV-2 via a survey to be completed by participating healthcare professionals. The survey includes sections on patient demographics, the diagnosis and treatment of COVID-19 and cancer as well as the evolution of both conditions.

The registry is open to institutions in Europe and other parts of the world, and is led by a steering committee comprising nine experts from institutions in France, Germany, Portugal, Switzerland, UK, and USA who specialize in different tumor types.

As stated on the website, a partnership between ESMO-CoCARE and the US-based CCC19 registry has been established “[t]o increase the rate at which information can be collected.”

ESMO adds: “For practical and organisational reasons, the two initiatives cover different geographical locations.”

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group

18 May 2020: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.

Related topics

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits